ObaClin ApS: Financial statements 2024
CVR: 43789244
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ObaClin ApS (CVR 43789244) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 0 and a net result of DKK -165,416 compared with DKK -12,988 the year before. Equity in the 2024 report amounted to DKK -138,404.
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -165,416
- Equity
- DKK -138,404
- Total Assets
- DKK 1,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 0 | -165 t. | -138 t. | - |
| 2023 | - | -3 t. | -13 t. | 27 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ObaClin ApS has published its annual report for 2023. Gross profit came to DKK -2,988, and the net result was DKK -12,988.
About ObaClin ApS
ObaClin ApS is a Danish company of the type Anpartsselskab based in Aalborg SV, founded in 2023. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Rikke Hagmann Schmidt. The company is owned by Rikke Hagmann Schmidt. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -165,416 the year before. Equity in the 2025 report amounted to DKK -138,404.